

1 A Holistic Approach to HPLC technique for addressing process impurities: review on Method
2 Development, Optimization, and Validation.

3 **Abstract**

4 High-Performance Liquid Chromatography (HPLC) has become an indispensable analytical
5 tool in pharmaceutical, environmental, and food sciences due to its precision, sensitivity, and
6 versatility. A holistic approach to HPLC method development, optimization, and validation
7 ensures reliable and reproducible results while meeting regulatory requirements. This review
8 outlines the critical steps in HPLC method development, emphasizing the importance of
9 understanding analyte properties, selecting appropriate chromatographic conditions, and fine-
10 tuning parameters for optimal performance. Key aspects of method optimization, such as
11 mobile phase composition, column selection, flow rate, and pH, are discussed to enhance
12 resolution and reduce analysis time. Additionally, the article delves into the rigorous validation
13 process, which includes assessing accuracy, precision, specificity, linearity, and robustness in
14 compliance with International Council for Harmonisation (ICH) guidelines. By integrating
15 systematic method development, experimental optimization, and thorough validation, this
16 holistic framework ensures efficient and high-quality analytical methods, driving
17 advancements in research and quality assurance across various industries.

18 **Keywords**

19 High Performance Liquid Chromatography, genotoxic potential impurities, N-nitroso compounds
20 pharmaceutical chemistry, methodology formulation. procedural validation.

21 **Background**

22 High-Performance Liquid Chromatography (HPLC) is an advanced analytical methodology
23 extensively used for the identification, quantification, and characterization of contaminants in
24 complex matrices. It is critical in the pharmaceutical industry, where rigorous regulatory
25 standards mandate the precise detection of process-related impurities, degradation products,

26 and genotoxic contaminants (GTCs) to ensure pharmaceutical safety and therapeutic efficacy.
27 Regulatory frameworks like ICH M7 highlight the importance of controlling GTCs [3],
28 including nitrosamines, which must be monitored at trace concentrations to minimize potential
29 carcinogenic hazards and comply with international safety regulations.

30 **Main Text**

31 **1. Introduction to HPLC**

32 High-Performance Liquid Chromatography (HPLC) is a chromatographic technique that
33 separates compounds based on interactions with a stationary phase, influenced by factors like
34 polarity, size, and structure [1]. It operates under high pressure, improving resolution and
35 sensitivity for complex samples [2]. HPLC is widely used in pharmaceuticals, biotechnology,
36 food safety, and environmental monitoring for its ability to provide high-throughput,
37 reproducible, and precise results.

38 In pharmaceuticals, HPLC is essential for quantifying active ingredients, impurities, degradation
39 products, and genotoxic contaminants (GTCs) [3]. The integration with mass spectrometry (LC-
40 MS) enhances sensitivity, enabling the detection of trace-level contaminants, ensuring drug
41 safety and regulatory compliance. Innovations like core-shell and monolithic columns improve
42 separation efficiency, facilitating the analysis of complex samples while meeting regulatory
43 standards [5].

44 **2. HPLC in Overcoming Analytical Obstacles: Perspectives and Strategies**

45 The adoption of HPLC in pharmaceutical and industrial quality control is constrained by a series
46 of analytical and technical challenges, including:

47 **2.1 Identification Quantification and Profiling of Genotoxic Impurities (GTIs) in**

48 **Pharmaceutical Compounds:**

49 Genotoxic impurities, which have the potential to induce DNA damage and are regarded as
50 potential carcinogens, must be detected at exceedingly low concentrations, often at sub-parts-

51 per-billion (ppb) levels [5]. Regulatory frameworks, such as ICH M7 [3], underscore the
52 imperative to utilize highly sensitive and precise analytical methodologies, such as HPLC, for
53 the detection and quantification of these impurities.

54 **2.2 Advanced techniques for the dissection and examination of multifaceted sample** 55 **matrices.:**

56 Advanced techniques for the dissection and examination of complex sample matrices using
57 High-Performance Liquid Chromatography (HPLC) include precise sample preparation methods
58 such as solid-phase extraction (SPE), which aids in isolating target analytes [1]. The application
59 of gradient elution enhances separation efficiency, particularly for complex samples containing
60 compounds with diverse polarities [2]. Coupling HPLC with highly sensitive detectors, such as
61 mass spectrometry (MS) or UV-Vis, ensures high specificity and sensitivity, which is crucial for
62 detecting trace impurities. The use of specialized columns and automated sample injection
63 systems further enhances resolution and reproducibility [4]. These innovations make HPLC a
64 powerful analytical tool in diverse industries.

65 The complexity of pharmaceutical products or drug substances can result in matrix effects that
66 hinder accurate detection of genotoxic impurities (GTIs). To effectively separate target
67 compounds from complex mixtures, advanced sample preparation techniques, such as solid-
68 phase extraction (SPE) and liquid-liquid extraction (LLE), are essential for isolating analytes of
69 interest [6,7].

70 **2.3 Innovation Demands:**

71 Identifying genotoxic impurities (GTIs) in pharmaceuticals requires advanced instruments, such
72 as High-Performance Liquid Chromatography (HPLC) coupled with Mass Spectrometry (LC-
73 MS) and Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS), for precise
74 trace-level analysis. These technologies provide high resolution and accuracy, ensuring

75 compliance with regulatory standards like ICH M7 [3]. Automated sample preparation systems
76 enhance efficiency and minimize contamination risks [6,7].

77 **3. Leading-edge methods for the quantification and characterization of genotoxic** 78 **impurities and nitrosamines in pharmaceutical drug substances.**

79 Leading-edge methods for the quantification and characterization of genotoxic impurities and
80 nitrosamines in pharmaceutical drug substances are critical for ensuring the safety and efficacy
81 of pharmaceutical products. Prominent examples include N-Nitroso dimethylamine (NDMA)
82 and N-Nitrosodiethylamine (NDEA) [11,12]. These methods often employ highly sensitive
83 techniques such as High-Performance Liquid Chromatography (HPLC) coupled with Mass
84 Spectrometry (MS), which provides exceptional resolution and specificity for detecting trace
85 levels of impurities. Additionally, advanced methods like Gas Chromatography-Mass
86 Spectrometry (GC-MS) and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
87 are used to quantify these impurities with high precision [1]. The integration of automated
88 sample preparation techniques, such as solid-phase extraction (SPE), further enhances efficiency
89 and accuracy, minimizing contamination and variability [6,7]. These state-of-the-art approaches
90 are crucial for meeting stringent regulatory guidelines, such as those outlined in ICH M7 [3], and
91 for ensuring the safe use of pharmaceutical products by detecting harmful impurities at levels
92 that could pose risks to human health [5].

93 **4. Analytical Technique Design:**

94 HPLC Analytical technique design focuses on developing efficient methods to achieve accurate
95 separation, detection, and quantification of target compounds in complex samples.

96 **4.1 Column Suitability:** Column suitability in HPLC is essential for achieving optimal
97 separation, resolution, and sensitivity of target analytes. The choice of column type of reversed-
98 phase, normal-phase, or ion-exchange depends on the chemical characteristics of the compounds
99 being analyzed and the required chromatographic performance. Key factors such as particle size,

100 pore size, and column length are critical for efficient separation and reduced analysis time [1]. As
101 such, evaluating column suitability is a crucial step in ensuring the success of HPLC analyses,
102 particularly when dealing with complex sample matrices [2].

103 **4.2 Mobile Phase Fine-tuning:** Mobile phase fine-tuning in HPLC is vital for enhancing the
104 separation efficiency and resolution of analytes. By adjusting factors such as solvent
105 composition, pH, and ionic strength, analysts can enhance peak shape, reduce retention time, and
106 improve overall chromatographic performance [1]. Fine-tuning the mobile phase is particularly
107 important for complex mixtures, where slight adjustments can significantly impact sensitivity
108 and selectivity [2]. Therefore, careful optimization of the mobile phase is essential for achieving
109 high-quality analytical results.

110 **4.3. Choice of Buffer:** choice of buffer in chromatographic methods is critical for maintaining a
111 stable pH environment during analysis. The buffer's pH range should align with the ionization
112 requirements of the analyte for optimal separation. Buffer capacity must be sufficient to resist pH
113 fluctuations caused by sample injection or mobile phase changes. Compatibility with the mobile
114 phase is essential to avoid interference with analyte interactions. Common buffers such as
115 phosphate, acetate, and citrate are tailored to specific analyte properties and experimental
116 conditions [1].

117 **4.4. pH optimization:** pH optimization in chromatography is essential for ensuring proper
118 ionization of analytes, impacting their separation and retention. The correct pH enhances
119 resolution and minimizes peak tailing. It is crucial for achieving consistent and reproducible
120 results in chromatographic analysis. pH selection depends on the analyte properties and the
121 chromatography method used [1].

122 **4.5. Contribution of organic modifiers:** The contribution of organic modifiers in
123 chromatography is crucial for adjusting the polarity of the mobile phase, which impacts analyte
124 retention and separation. Organic solvents help enhance the solubility of hydrophobic

125 compounds and improve peak shape. They also play a role in controlling the interaction between
126 analytes and the stationary phase, optimizing resolution [1].

127 **4.6. Opting for Detectors in Chromatography:** The selection of detectors in chromatography is
128 based on the analyte's chemical properties, sensitivity requirements, and the type of analysis.
129 Common detectors, such as UV/Vis, fluorescence, and refractive index detectors, vary in
130 selectivity and sensitivity. The detector's linear range and response time are critical for accurate
131 quantification, particularly in trace analysis. Compatibility with the mobile phase and sample
132 matrix ensures minimal interference and accurate results [1].

133 **4.7. Preparation of Analytical Samples:**

134 Sample preparation for HPLC and LC-MS/MS involves isolating the analyte from the sample
135 matrix using techniques like extraction or filtration. It may also include steps like dilution,
136 concentration, or derivatization to optimize analyte detection and ensure compatibility with the
137 chromatographic system. Proper sample preparation is essential for minimizing matrix
138 interference and improving sensitivity. These steps enhance the reliability and accuracy of results
139 in both techniques [1].

140 **5. Validation of Analytical Techniques:**

141 Validation in chromatography refers to the process of confirming that a particular analytical
142 method is suitable for its intended purpose. It involves a series of tests to ensure that the method
143 is accurate, precise, reliable, and reproducible. For pharmaceutical analyses, validation ensures
144 that the method consistently delivers results that meet regulatory requirements [16].

145 Key components of method validation in chromatography include:

146 **Accuracy:** The closeness of the measured value to the true value.

147 **Precision:** The reproducibility of results under the same conditions.

148 **Specificity:** The ability to measure the analyte in the presence of other substances in the sample.

149 **Sensitivity:** The method's ability to detect low concentrations of the analyte.

150 **Linearity:** The relationship between analyte concentration and detector response over a specified
151 range.

152 **Range:** The interval between the lowest and highest concentrations of analyte that can be
153 reliably measured.

154 **Robustness:** The method's ability to remain unaffected by small variations in operational
155 conditions (e.g., temperature, mobile phase composition).

156 Validation is an essential part of method development to ensure compliance with regulatory
157 standards such as those set by the FDA or ICH [16].

158 **6. Refining HPLC methodologies for expandability in pharmaceutical and industrial** 159 **applications.**

160 Refining HPLC methodologies for expandability is crucial for efficient and cost-effective
161 pharmaceutical and industrial production. As demands increase, HPLC methods must be optimized to
162 handle larger sample volumes, higher throughput, and diverse formulations without sacrificing
163 precision. Key improvements include developing robust, high-resolution columns, optimizing mobile
164 phases, and integrating automation for better productivity and reproducibility [8]. These methods
165 must also adapt to varying analytical challenges, from APIs to complex impurities [9]. By advancing
166 HPLC techniques for scalability, industries can meet growing demands while ensuring product
167 quality and regulatory compliance. Below are key areas of focus in optimizing HPLC for scalability:

168 **6.1. Cost-Effectiveness and Sustainability:** Scaling up HPLC methods requires focusing on
169 cost-effectiveness and sustainability. This includes using lower-cost reagents, optimizing solvent
170 use, and reducing waste. Methods that minimize sample preparation and energy consumption
171 also contribute to environmental and economic sustainability [10].

172 **6.2. Operational Lifespan of Analytical Tools:** The operational lifespan of analytical tools is
173 critical for ensuring consistent performance and minimizing maintenance, ensuring consistent
174 performance and minimizing maintenance costs in long-term applications [8].

175 **6.3. Automation and High-Throughput Integration:** Automation is key to meeting
176 pharmaceutical and industrial scalability demands, enhancing throughput and reducing manual
177 intervention. Automated injectors, sample preparation systems, and high-throughput HPLC
178 systems ensure consistent processing of larger sample volumes while maintaining analysis
179 integrity and improving workflow efficiency [8].

180 **7. Monetary Considerations:** The adoption of HPLC and LC-MS technologies presents
181 significant monetary considerations that extend beyond initial investment costs. While LC-MS
182 offers superior sensitivity and advanced analytical capabilities, it comes with higher operational,
183 maintenance, and data management expenses compared to HPLC. Careful cost-benefit analysis
184 is essential when selecting the appropriate technique, taking into account the specific needs of
185 the analysis, available budget, and long-term operational goals. By optimizing resource
186 allocation and operational efficiency, the financial impact of these technologies can be
187 effectively managed, ensuring their sustainable use in analytical applications.

188 Economic factors play a crucial role in the adoption of HPLC techniques. While the initial
189 investment in LC-MS systems is high, their sensitivity, specificity, and automation capabilities
190 provide significant long-term benefits [5].

191 **7.1. Recurring Consumables:** Recurring costs, including mobile phase solvents and the periodic
192 replacement of columns [10].

193 **7.2. Automation:** Streamlined Operations reduce manual intervention by automating tasks such
194 as sample injection, mobile phase delivery, and data processing in HPLC analysis [8].

195 Through streamlined operations, labour costs are minimized as processes like sample preparation
196 and data analysis become more efficient.

197 The implementation of streamlined operations enhances overall productivity, reducing both time
198 and resource consumption.

199 **7.3. Abidance by Regulations:** Abidance by regulatory standards ensures compliance with
200 established limits, thereby mitigating the risk of infringement of regulations [12,16].

201 The organization's strict abidance by regulations reflects its commitment to maintaining high-
202 quality standards.

203 **8. Vision for the Future.**

204 Emerging era of HPLC and LC-MS/MS in pharmaceuticals holds promising advancements,
205 particularly in drug development, quality control, and regulatory compliance. Enhanced
206 sensitivity and resolution in both technologies will allow for more accurate detection of
207 impurities and better quantification of drug compounds at lower concentrations, including
208 genotoxic impurities such as nitrosamines [11] ensuring higher safety standards [14]. Automation
209 and integration of these techniques will streamline workflows, increase throughput, and reduce
210 operational costs, making pharmaceutical testing more efficient and cost-effective. Moreover, the
211 incorporation of green chemistry practices, such as eco-friendly solvents and energy-efficient
212 systems, aligns with the growing demand for sustainability in pharmaceutical manufacturing
213 [13]. As both technologies evolve, they will continue to play a critical role in meeting stringent
214 regulatory requirements and supporting the development of personalized medicine. The
215 increased accessibility and affordability of these technologies will democratize their use,
216 benefiting smaller labs and facilitating research and diagnostics across the pharmaceutical
217 industry.

218 **8.1. AI-driven Technology:** Artificial Intelligence is becoming more integral in HPLC to
219 improve analytical efficiency. Machine learning algorithms automatically adjust
220 chromatographic parameters like flow rate and gradient profiles for optimal performance. In
221 addition, AI-driven systems facilitate the interpretation of complex datasets, enhancing data
222 accuracy and accelerating the analysis process, which leads to better-informed decision-making
223 [15].

224 **8.2. Compact HPLC Systems:** Compact HPLC systems provide considerable benefits for on-
225 site quality control and fast impurity testing. Compact HPLC units allow for real-time analysis of
226 active pharmaceutical ingredients (APIs) and excipients directly at manufacturing facilities,
227 ensuring adherence to regulatory standards and enabling the swift identification of contaminants
228 [7].

229 **8.3. State-of-the-art Detectors and Sampling Techniques:** Innovative sampling methods,
230 including solid-phase microextraction (SPME) and needle-based devices, significantly improve
231 sensitivity, precision, and the range of applications in pharmaceutical analysis [1].

232 **8.4. Sustainable Practices:** The adoption of hydrogen as a mobile phase modifier and the
233 development of eco-friendly stationary phases align with green chemistry principles [8].

234 CONCLUSIONS

235 High-performance liquid chromatography (HPLC) is advancing to meet the growing challenges
236 of impurity analysis in the pharmaceutical industry, driven by innovations in automation,
237 miniaturization, and sustainability. The adoption of AI-driven analytics is revolutionizing data
238 interpretation, providing faster and more precise results while reducing human error.

239 Additionally, miniaturization improvements are making HPLC systems more accessible and
240 efficient, offering enhanced cost-effectiveness and ease of use. Sustainable approaches, such as
241 utilizing mobile phase modifiers and developing eco-friendly stationary phases, align with green
242 chemistry principles, fostering environmentally responsible practices. These advancements
243 further solidify HPLC's essential role in ensuring product quality, maintaining regulatory
244 compliance, and supporting environmental stewardship.

245 List of Abbreviations

246 **HPLC:** High Performance Liquid Chromatography

247 **GTIs:** Genotoxic Impurities

248 **ICH:** International Council for Harmonisation

249 **LC-MS:** Liquid Chromatography-Mass Spectrometry

250 **Declarations**

251 **Acknowledgments:**

252 I would like to acknowledge Dr B. Jainendra Kumar (Associate professor, Anurag University),
253 who guiding me in Ph. D work.

254 I would like to acknowledge Dr G. Sampath Kumar Reddy (Head- AR&D & Quality, Aurore
255 Life Sciences Private Limited), who encouraged and facilities to do research work.

256 I would like to acknowledge Mr J. Rajendar Rao (MD &CEO, Aurore Life Sciences Private
257 Limited), who providing facilities to do research work.

258 **Endorsement for acknowledgment:**

259 I have received the approval to acknowledge from all the persons mentioned in the
260 “Acknowledgements” section.

261 **Endorsement for Publication:**

262 All authors endorsement to publication.

263 **Roles of the Authors:**

264 P. Chandrashekhar Reddy collected and analysed the data and wrote the manuscript. He is the
265 lead author and showed strong commitment to the work. Dr. G Sampath Kumar Reddy has made
266 critical suggestions to the conception and substantively revised the work. Dr B. Jainendra Kumar
267 was the supporting pillar for writing manuscript and reviewed the work. All authors have read
268 and approved the manuscript.

269 **Monetary Support**

270 No Monetary Support

271 **Data and Resource Accessibility**

272 As no data sets were generated or analyzed in this study, data sharing is not relevant.

273 **Consent and Ethical Authorization to Participate**

274 Not applicable.

275 **Conflicts of Interest**

276 The authors proclaim no conflicts interests.

277 **Authors' details:**

278 1) Department of Chemistry, Anurag University, Hyderabad, India.

279 2) Department of Analytical Research and Development, Aurore Life Sciences Private

280 Limited, Hyderabad, India

281 **References:**

- 282 1. Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2010). *Introduction to modern liquid*
283 *chromatography* (3rd ed.). Wiley.
- 284 2. Lacher, S. K., & Schomburg, G. (2016). High-pressure liquid chromatography in analytical
285 chemistry. In *Springer handbook of enzyme technology* (pp. 111-120). Springer.
- 286 3. ICH Guidelines M7. (2018). *Genotoxicity testing and risk assessment for pharmaceuticals*.
- 287 4. Dvorkin, L., & Nivens, D. E. (2015). Monolithic columns in HPLC: Innovations and applications.
288 *Journal of Chromatographic Science*, 53(4), 481-487.
289 <https://doi.org/10.1093/chromsci/bmu234>
- 290 5. International Council for Harmonisation [ICH]. (2018). *ICH M7: Genotoxicity testing and risk*
291 *assessment for pharmaceuticals*. Retrieved from
292 https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf
- 293 6. Yang, L., & Zhang, X. (2020). Recent advances in solid-phase extraction techniques for
294 pharmaceutical analysis. *Analytica Chimica Acta*, 1130, 135-145.
295 <https://doi.org/10.1016/j.aca.2020.01.029>.
- 296 7. Tse, R. E., & D'Agostino, L. A. (2019). Liquid-liquid extraction: Techniques and applications in
297 analytical chemistry. *Journal of Chromatography A*, 1601, 86-100.
298 <https://doi.org/10.1016/j.chroma.2019.01.029>.

- 299 8. Zhang, Y., et al. (2024). Operator-free HPLC automated method development guided by Bayesian
300 optimization algorithms. *Digital Discovery*, 3(8), 1591-1601.
301 <https://doi.org/10.1039/D4DD00062E>.
- 302 9. Hites, R. A. (2017). *Elements of environmental chemistry* (2nd ed.). Wiley.
- 303 10. Alexander, A. J.; Waeghe, T. J.; Himes, K. W.; Tomasella, F. P.; Hooker, T. F. Modifying
304 Conventional High-Performance Liquid Chromatography Systems to Achieve Fast Separations
305 with Fused-Core Columns: A Case Study. *J. Chromatogr. A* **2021**, 1218, 5456–5469.
306 [DOI: 10.1016/j.chroma.2011.06.026](https://doi.org/10.1016/j.chroma.2011.06.026).
- 307 11. Patocka, J., & Kuca, K. (2018). Genotoxic impurities and nitrosamines in pharmaceutical drug
308 substances: N-Nitroso dimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA).
309 *Environmental Toxicology and Pharmacology*, 62, 1-10.
310 <https://doi.org/10.1016/j.etap.2018.02.006>.
- 311 12. European Medicines Agency [EMA]. (2020). *Questions and answers on nitrosamines as*
312 *impurities in human medicinal products*. <https://www.ema.europa.eu>.
- 313 13. Patocka, J., & Kuca, K. (2018). Advances in analytical techniques for the detection of genotoxic
314 impurities in drug substances. *Environmental Toxicology and Pharmacology*, 59, 33–40.
315 <https://doi.org/10.1016/j.etap.2017.11.009>.
- 316 14. Singh, S. P., & Kaur, G. (2020). Recent advances in HPLC and LC-MS for pharmaceutical
317 analysis. *Journal of Pharmaceutical and Biomedical Analysis*, 178, 112900.
318 <https://doi.org/10.1016/j.jpba.2019.112900>.
- 319 15. Singh, Y. R., Shah, D. B., Maheshwari, D. G., Shah, J. S., & Shah, S. (2023). Advances in AI-
320 Driven Retention Prediction for Different Chromatographic Techniques: Unraveling the
321 Complexity. *Critical Reviews in Analytical Chemistry*, 54(8), 3559–3569.
322 <https://doi.org/10.1080/10408347.2023.2254379>.
- 323 16. International Conference on Harmonisation (ICH) (2005). *Validation of Analytical Procedures:*
324 *Text and Methodology Q2(R1)*.